Arcturus therapeutics reports q3 loss per share of $0.56

Arcturus therapeutics announces third quarter financial results and provides corporate update.q3 loss per share $0.56.q3 earnings per share estimate $-0.36 -- refinitiv ibes data.ind application for arct-810, a treatment of ornithine transcarbamylase (otc) deficiency, is on track for q1 2020 filing.at september 30, 2019, arcturus had cash and cash equivalents totaling $74.2 million.

ARCT Ratings Summary

ARCT Quant Ranking